Clinical Trial Update: Itacitinib for the Prevention of Graft Versus Host Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Itacitinib to prevent graft-versus-host disease after hematopoietic stem cell transplantation is active but not recruiting. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Itacitinib (itacitinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hematologic and Lymphocytic Disorder | Phase 2 | Status: ACTIVE_NOT_RECRUITING